WO2024253944A3 - Protéine de fusion d'interleukine-15 et procédés d'utilisation - Google Patents

Protéine de fusion d'interleukine-15 et procédés d'utilisation Download PDF

Info

Publication number
WO2024253944A3
WO2024253944A3 PCT/US2024/031723 US2024031723W WO2024253944A3 WO 2024253944 A3 WO2024253944 A3 WO 2024253944A3 US 2024031723 W US2024031723 W US 2024031723W WO 2024253944 A3 WO2024253944 A3 WO 2024253944A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion protein
interleukin
well
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/031723
Other languages
English (en)
Other versions
WO2024253944A2 (fr
Inventor
Jianwei Zhu
Shusheng Wang
Kaiyong YANG
Haiqiu HUANG
Yueqing XIE
Hua Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jecho Laboratories Inc
Original Assignee
Jecho Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jecho Laboratories Inc filed Critical Jecho Laboratories Inc
Priority to CN202480037283.9A priority Critical patent/CN121240886A/zh
Priority to EP24819810.3A priority patent/EP4724099A2/fr
Publication of WO2024253944A2 publication Critical patent/WO2024253944A2/fr
Publication of WO2024253944A3 publication Critical patent/WO2024253944A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgation propose des protéines de fusion IL-15, ainsi que des compositions les comprenant. La divulgation propose en outre des méthodes de traitement et/ou de prévention d'une immunodéficience, ainsi que des méthodes d'immunothérapie anticancéreuse chez un sujet, la méthode consistant à administrer une protéine de fusion telle que décrite dans la description.
PCT/US2024/031723 2023-06-06 2024-05-30 Protéine de fusion d'interleukine-15 et procédés d'utilisation Ceased WO2024253944A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480037283.9A CN121240886A (zh) 2023-06-06 2024-05-30 白细胞介素-15融合蛋白及其使用方法
EP24819810.3A EP4724099A2 (fr) 2023-06-06 2024-05-30 Protéine de fusion d'interleukine-15 et procédés d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471370P 2023-06-06 2023-06-06
US63/471,370 2023-06-06

Publications (2)

Publication Number Publication Date
WO2024253944A2 WO2024253944A2 (fr) 2024-12-12
WO2024253944A3 true WO2024253944A3 (fr) 2025-01-09

Family

ID=93794629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031723 Ceased WO2024253944A2 (fr) 2023-06-06 2024-05-30 Protéine de fusion d'interleukine-15 et procédés d'utilisation

Country Status (3)

Country Link
EP (1) EP4724099A2 (fr)
CN (1) CN121240886A (fr)
WO (1) WO2024253944A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120177595A1 (en) * 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US20140113370A1 (en) * 2011-04-13 2014-04-24 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US20190365861A1 (en) * 2018-04-18 2019-12-05 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2021030688A1 (fr) * 2019-08-15 2021-02-18 Igm Biosciences, Inc. Molécules de liaison multimériques immunostimulatrices
WO2021142476A1 (fr) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Polypeptides à chaîne unique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120177595A1 (en) * 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US20140113370A1 (en) * 2011-04-13 2014-04-24 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US20190365861A1 (en) * 2018-04-18 2019-12-05 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2021030688A1 (fr) * 2019-08-15 2021-02-18 Igm Biosciences, Inc. Molécules de liaison multimériques immunostimulatrices
WO2021142476A1 (fr) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Polypeptides à chaîne unique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLES ET AL.: "Prevention of Human Rhinovirus Infection by Multivalent Fab Molecules Directed against ICAM-1", ANTIMICROB AGENTS CHEMOTHER., vol. 47, no. 5, 2003, pages 1503 - 1508, XP009015720, DOI: 10.1128/AAC.47.5.1503-1508.2003 *
CHEN ET AL.: "A targeted IL -15 fusion protein with potent anti-tumor activity", CANCER BIOL THER., vol. 16, no. 9, 2015, pages 1415 - 1421, XP055460315, DOI: 10.1080/15384047.2015.1071739 *
HSU FEI-TING, LIU YU-CHANG, TSAI CHANG-LIANG, YUEH PO-FU, CHANG CHIH-HSIEN, LAN KENG-LI: "Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma", CANCERS, vol. 13, no. 8, CH , pages 1789 - 1789-25, XP093262730, ISSN: 2072-6694, DOI: 10.3390/cancers13081789 *

Also Published As

Publication number Publication date
EP4724099A2 (fr) 2026-04-15
WO2024253944A2 (fr) 2024-12-12
CN121240886A (zh) 2025-12-30

Similar Documents

Publication Publication Date Title
WO2021163064A3 (fr) Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
WO2021158619A8 (fr) COMPOSÉS DE LIAISON À IL-7Rα
WO2020072821A3 (fr) Protéines de fusion fc hétérodimères d'il -12
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
AU2019255744A8 (en) IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof
WO1999040188A3 (fr) Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
WO2003076567A3 (fr) Proteines hybrides g-csf heterologues
WO2022235622A3 (fr) Protéines de fusion ciblant cd20 et leurs méthodes d'utilisation
WO2021181233A3 (fr) Protéines de fusion et leurs utilisations
ZA202304591B (en) Anti-cd73 antibody and use thereof
WO2022023538A3 (fr) Polypeptides inhibiteurs de pd-l1 à demi-vie sérique prolongée
MX2022009101A (es) Proteinas heterodimericas con mutaciones fc.
WO2023043978A3 (fr) Protéines de fusion de l'il-12 ciblant caix et leurs méthodes d'utilisation
WO2025038726A3 (fr) Variants de l'interleukine 21
MX2024002147A (es) Proteina de fusion que contiene anticuerpo anti-tigit y tgf-?r, y composicion farmaceutica y uso de las mismas.
CA2554195A1 (fr) Peptide provenant du recepteur du facteur de croissance epidermique (egfr)
WO2023235882A3 (fr) Immunothérapie ciblant des antigènes egfr
AU2363301A (en) Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
WO2023159136A3 (fr) Modification d'épitope de récepteurs de surface cellulaire
PH12023553215A1 (en) Antibody-nkg2d ligand domain fusion protein
AU2003217758A1 (en) Cytokines and cytokine receptors with reduced immunogenicity
WO2021234676A4 (fr) Composés et procédés pour supprimer une réponse immunitaire à des substances contenant du polyéthylène glycol
WO2024118539A3 (fr) Interleukine-10 modifiée et ses protéines de fusion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24819810

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2025570808

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024819810

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024819810

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819810

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819810

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819810

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024819810

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 2024819810

Country of ref document: EP